Sepsis and septic shock remain major causes of organ dysfunction and death. The EPOS‑1 trial tested a novel therapeutic concept: pharmacologically enhancing host disease tolerance rather than directly targeting pathogens. Preclinical models indicated that low doses of anthracyclines such as epirubicin can increase tissue damage control and reduce sepsis severity independent of pathogen burden. Because epirubicin is myelotoxic at oncologic doses, the clinical question addressed was whether substantially lower, single doses can be given safely to patients with sepsis.
EPOS‑1 was a randomized, double‑blind, placebo‑controlled, phase IIa dose‑escalation study conducted at five German university hospitals. The trial was registered (NCT05033808) and approved by the ethics committee of Jena University Hospital and by the German health authorities (BfArM) as stated in the source. The study employed a 4:1 randomization favoring active treatment over placebo and used three consecutive dose‑escalation phases.
Adults meeting Sepsis‑3 criteria were eligible if randomized within 48 hours of diagnosis. According to the report, 854 patients were screened for eligibility. Thirty‑two patients were randomized and 31 were included in the primary analysis population. Enrollment began October 19, 2022, and the last follow‑up reported in the source occurred May 21, 2025.
Participants randomized to active treatment received a single intravenous infusion of epirubicin at one of three dose levels depending on the study phase: 3.75 mg/m2, 7.5 mg/m2, or 15 mg/m2. Placebo recipients received matching infusion in addition to standard of care. Dose escalation was sequential across phases as detailed in the trial design.
The predefined primary endpoint was 14‑day myelotoxicity, chosen because epirubicin’s principal safety concern at therapeutic doses is bone marrow suppression. Secondary and exploratory outcomes included 90‑day mortality, degree of organ dysfunction measured by SOFA score, pharmacokinetic/pharmacodynamic (PK/PD) modelling, and cytokine release profiling.
Of the 32 randomized participants, allocation to groups was: six placebo, nine at 3.75 mg/m2, nine at 7.5 mg/m2, and eight at 15 mg/m2 in the epirubicin arms. Thirty‑one participants were included in the primary analysis population according to the source report.
No myelotoxicity was observed in any treatment group within the 14‑day primary observation window. The authors report that low‑dose epirubicin was not associated with increased myelotoxicity in this cohort.
The source states that 90‑day mortality and SOFA scores were not significantly different between groups. The abstract provides these outcome summaries but does not detail effect sizes, confidence intervals, or adjusted analyses in the text provided here.
Across the trial, 39 serious adverse events (SAEs) occurred in the epirubicin group; investigators assessed two of these SAEs as possibly related to epirubicin. The source did not list all individual SAEs or provide event‑level detail in the abstract portion included here.
PK/PD modelling and cytokine release were specified as exploratory outcomes. The abstract notes these assessments were performed, but detailed PK/PD results and cytokine data were not reported in the source text provided here.
The trial received ethical approval from the Jena University Hospital ethics committee (approval dated December 20, 2021, reference given in the source) and regulatory approval from BfArM (November 8, 2021). Funding was declared from the Bundesministerium für Forschung, Technologie und Raumfahrt. One author disclosed inventorship on an international patent related to the use of anthracyclines for sepsis; all other authors reported no competing interests in the abstract.
In this small randomized, placebo‑controlled phase IIa trial, single low doses of epirubicin administered to patients with sepsis or septic shock were not associated with increased myelotoxicity within 14 days. No significant differences were observed in 90‑day mortality or SOFA scores in the reported dataset. Two SAEs were judged possibly related to epirubicin. These results support the tolerability of the studied low doses in this select cohort but do not establish clinical efficacy; further work is required to characterize PK/PD, immune effects, and potential clinical benefit in larger samples.
Key limitations apparent from the source include the small randomized sample (32 randomized, 31 analyzed) and limited reporting of detailed PK/PD and cytokine results in the abstract. The trial tested single‑dose administration and three low dose levels; whether different dosing schedules, larger cohorts, or targeted subpopulations would demonstrate clinical benefit remains to be determined. The authors’ final interpretation in the source is cautious: absence of increased myelotoxicity with low‑dose epirubicin in this phase IIa cohort warrants further investigation but does not demonstrate efficacy.